BioTime, Inc.
LCTX US53566P1093
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 27% | -53% | -11% | -54% | 13% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Samuel George A. Iii SR OFF |
0.60 USD |
15,000 Bought |
9,000 USD |
26/11/2024 | 26/11/2024 |
| Howe Jill Ann CFO |
0.59 USD |
15,000 Bought |
8,850 USD |
26/11/2024 | 26/11/2024 |
| Mulroy Michael H. |
0.57 USD |
40,000 Bought |
22,640 USD |
22/11/2024 | 22/11/2024 |
| Culley Brian M CEO |
0.60 USD |
40,000 Bought |
24,000 USD |
21/11/2024 | 21/11/2024 |
| Howe Jill Ann CFO |
0.89 USD |
10,500 Bought |
9,345 USD |
16/08/2024 | 16/08/2024 |
| Culley Brian M CEO |
1.05 USD |
10,000 Bought |
10,500 USD |
24/05/2024 | 24/05/2024 |
| Bailey Don M O |
1.04 USD |
96,155 Bought |
100,001 USD |
08/02/2024 | 08/02/2024 |
| Jayasuriya Anula O |
1.09 USD |
10,000 Bought |
10,900 USD |
29/12/2023 | 29/12/2023 |